Active Biotech 将来の成長

Future 基準チェック /26

Active Biotech収益と収益がそれぞれ年間62.1%と134.1%増加すると予測されています。

主要情報

62.1%

収益成長率

n/a

EPS成長率

Biotechs 収益成長	42.4%
収益成長率	134.1%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	23 Oct 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:BTPC - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	28	-2	N/A	-2	1
12/31/2025	9	-27	N/A	-27	1
12/31/2024	N/A	-39	N/A	-41	1
9/30/2024	N/A	-42	-40	-40	N/A
6/30/2024	N/A	-44	-42	-42	N/A
3/31/2024	N/A	-45	-45	-45	N/A
12/31/2023	N/A	-46	-46	-46	N/A
9/30/2023	N/A	-48	-48	-48	N/A
6/30/2023	N/A	-51	-50	-50	N/A
3/31/2023	N/A	-54	-51	-51	N/A
12/31/2022	N/A	-58	-55	-55	N/A
9/30/2022	N/A	-60	-57	-57	N/A
6/30/2022	N/A	-57	-55	-55	N/A
3/31/2022	N/A	-56	-53	-53	N/A
12/31/2021	N/A	-50	-46	-46	N/A
9/30/2021	6	-38	-35	-35	N/A
6/30/2021	6	-35	-33	-33	N/A
3/31/2021	6	-32	-29	-29	N/A
12/31/2020	7	-32	-32	-32	N/A
9/30/2020	1	-39	-38	-38	N/A
6/30/2020	2	-40	-37	-37	N/A
3/31/2020	3	-36	-40	-40	N/A
12/31/2019	8	-34	-36	-36	N/A
9/30/2019	12	-32	-35	-35	N/A
6/30/2019	16	-31	-37	-37	N/A
3/31/2019	21	-35	-38	-38	N/A
12/31/2018	20	-37	-41	-41	N/A
9/30/2018	21	-88	-41	-41	N/A
6/30/2018	21	-88	N/A	-43	N/A
3/31/2018	20	-103	N/A	-44	N/A
12/31/2017	20	-109	N/A	-46	N/A
9/30/2017	22	-63	N/A	-52	N/A
6/30/2017	21	-67	N/A	-57	N/A
3/31/2017	20	-59	N/A	-61	N/A
12/31/2016	19	-60	N/A	-73	N/A
9/30/2016	17	-86	N/A	-86	N/A
6/30/2016	18	-97	N/A	-123	N/A
3/31/2016	17	-152	N/A	-187	N/A
12/31/2015	16	-194	N/A	-218	N/A
9/30/2015	14	-210	N/A	-245	N/A
6/30/2015	12	-243	N/A	-256	N/A
3/31/2015	11	-229	N/A	-243	N/A
12/31/2014	10	-232	N/A	-267	N/A
9/30/2014	12	-257	N/A	-157	N/A
6/30/2014	116	-171	N/A	-159	N/A
3/31/2014	116	-194	N/A	-170	N/A
12/31/2013	116	-212	N/A	-102	N/A

アナリストによる今後の成長予測

収入対貯蓄率: BTPC今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: BTPC今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: BTPC今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: BTPCの収益 ( 134.1% ) German市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: BTPCの収益 ( 134.1% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BTPCの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Active Biotech 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

No longer forecast to breakeven

Forecast breakeven date pushed back to 2025

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Recent updates

New major risk - Financial position

New major risk - Market cap size

Active Biotech AB (Publ) Reports Intention Inaugural Interocular Concentrations Achieves in A Clinical Bylistribution Study of Laquinimod Eye Drops

No longer forecast to breakeven

Active Biotech Provides Update on the Clinical Phase Ib/IIa Study with Tasquinimod in Relapsed Refractory Multiple Myeloma

Active Biotech Enters Agreement for A Clinical Study of Tasquinimod in Myelofibrosis

Active Biotech AB (publ) Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops

No longer forecast to breakeven

New major risk - Revenue and earnings growth

Active Biotech AB (publ), Annual General Meeting, May 22, 2024

New minor risk - Shareholder dilution

Active Biotech AB (Publ) Provides Update on the Scheduled Clinical Program for 2024

Active Biotech AB (Publ) Appoints Mats Arnhög and Petter Wingstrand to Nomination Committee

Forecast breakeven date pushed back to 2025

Active Biotech AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 51.135046 million.

Active Biotech AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 51.135046 million.

New minor risk - Profitability

Forecast to breakeven in 2024

Active Biotech AB (publ) Enters into Clinical Trial Collaboration Agreement for a Clinical Study with Tasquinimod in Myelofibrosis

Insufficient new directors

Active Biotech Announces Positive Interim Data from an Ongoing Study with Tasquinimod in Relapsed and Refractory Multiple Myeloma

Active Biotech AB (Publ) Confirms Positive Clinical Safety Profile of Laquinimod Eye Drops

Active Biotech AB (publ) to Report First Half, 2023 Results on Aug 24, 2023

Active Biotech's Announces Nomination Committee

Forecast to breakeven in 2024

Active Biotech AB (publ) to Report Fiscal Year 2022 Results on Feb 09, 2023

Active Biotech AB (Publ) Announces Successful Completion of the First Stage of the Phase Iia Clinical Trial of Naptumomab in Combination with Docetaxel and the Study Is Now Enrolling into the Second Stage

Active Biotech AB (publ) announces that Food and Drug Administration has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis

High number of new and inexperienced directors

Active Biotech AB (publ) to Report Q3, 2022 Results on Nov 03, 2022

Active Biotech Announces First Patient Dosed in the Combination Part of the Phase Ib/IIa Study of Tasquinimod in Multiple Myeloma

Active Biotech AB (publ) Announces First Subject Dosed in Phase I Clinical Study with Eye-Drop Formulation of Laquinimod

Active Biotech AB (publ) Provides Status Update of its Clinical Naptumomab Project

Independent Chairman of the Board recently bought €26k worth of stock

New 90-day high: €0.25

Active Biotech Receive Milestone Payment from Neotx

Active Biotech AB Appoints Elaine Sullivan as A Director

Earnings released

New 90-day high - €0.32

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘